Search Results for 'Merck, Pfizer Form Diabetes Pact'

Search For:
Refine by Dates:
From: To:
Refine By Content:

  • Merck, Pfizer Finalize Deal To Co-promote Xalkori

    April 7, 2015
    Will roll-out in two waves

  • KineMed, Pfizer Extend Diabetes Pact

    June 4, 2014
    Will continue to explore new approaches in metabolic disease

  • Covance, Ingenuity Enter NGS Data Pact

    February 23, 2011
    Ingenuity Systems has entered a research collaboration with Covance Genomics Laboratory for next-generation sequencing (NGS) data analysis.

  • PPD, Janssen Enter Drug Development Pact

    November 17, 2009
    PPD, Inc. has entered an agreement with Janssen Pharmaceutica to develop and commercialize two Phase II therapeutic compounds, one for diarrhea-predominant irritable bowel syndrome (IBS-d) and one for complicated skin and skin structure and respiratory in

  • Lilly, Transition Enter Diabetes Pact

    March 14, 2008
    Eli Lilly and Co. and Transition Therapeutics, Inc. have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize Transition's gastrin-based therapies, including the lead compound TT-…

  • Pfizer, BMS Finalize Metabolic Pact

    August 27, 2007
    Pfizer and Bristol-Myers Squibb have finalized their collaboration agreement to research, develop and commercialize DGAT-1 inhibitors. Pfizer's DGAT- 1 discovery program includes advanced preclinical compounds with potential applications for the trea…

  • Merck, Idera Form TLR Pact

    December 11, 2006
    Merck has formed a broad collaboration with Idera Pharmaceuticals to research, develop and commercialize Idera's Toll-like Receptor (TLR) agonists by incorporating them in therapeutic and prophylactic vaccines being developed by Merck for oncology, i…

  • Pfizer, TransTech Enter RAGE Pact

    September 18, 2006
    Pfizer and TransTech Pharma have entered into a license agreement for the development and commercialization of several of TransTech's small and large molecule compounds. These compounds target the receptor for advanced glycation endproducts (RAGE) an…

  • ImClone, Merck KGaA Revise Erbitux Pact

    July 21, 2006
    ImClone Systems and Merck KGaA have revised their licensing agreement for cancer drug Erbitux. Under the terms of the new agreement, Merck will sublicense certain intellectual property rights from ImClone related to the development of antibodies tar…